The United States and United Kingdom Agree to Duty-Free Deal on Medicines.
The United Kingdom and the United States have forged a important trade agreement that will maintain no levies on UK drug products entering the US market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has committed to raise funding on medicines through the National Health Service (NHS). This commitment secures that duties on these crucial exports will stay at zero for a period of the next three years.
This agreement follows earlier statements to hike import taxes on branded pharmaceutical products, with figures mentioned up to one hundred percent.
"This agreement with the Britain bolsters the worldwide climate for cutting-edge drugs and introduces much-needed fairness to American-British pharmaceutical trade," a statement said.
Economic Impact
Medicines constitute one of the the United Kingdom's biggest exports to the America, which is easily the primary buyer for major British pharmaceutical firms.
Statistics reveal that in the year to the end of last September, the UK shipped medicines valued at £11.1bn to the US. This value represented a significant portion of all goods exports in that period.
"This deal secures work, stimulates funding and sets the stage for the UK to establish itself as a global hub for life sciences," a minister commented.
Key NHS Changes
The pact involves several notable changes from the UK:
- Higher Cost Ceiling: The UK will lift the price threshold at which it considers new medicines to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a goal to raise total health service expenditure on drugs from 0.3 percent of the national economy to 0.6 percent over the next decade.
- Payback Limit: The amount pharmaceutical firms must pay back to the NHS to stay within budget will be restricted at fifteen percent. Last year, repayments exceeded 20%.
Recent Tensions
The pact comes amid a ongoing dispute between the pharmaceutical industry and the UK government over drug pricing and approval rates.
This friction were heightened by arguments that American customers were paying a premium for the same drugs than patients in the other developed nations.
Over the last 18 months, several large pharmaceutical investments in the UK have been halted or abandoned, while multi-billion-dollar investments have been announced toward American operations.
The Science Minister stated that the NHS had to spend more on treatments, noting that its budget allocation on drugs had shrunk as a percentage of its resources over the previous ten-year period.
